Pharmacoeconomic evaluation of original and generic temozolomide capsules in the treatment of glioma

Ming Gu; Changdong Diao; Mitchell A. Sullivan; Haixia Zhu; Qi Yuan; Jinmei Liu; Shijun Li; Yu Zhang; Bin Deng; Chen Shi

doi:10.1016/j.ipha.2023.04.006

Intelligent Pharmacy ›› 2023, Vol. 1 ›› Issue (1) : 26 -31. DOI: 10.1016/j.ipha.2023.04.006

Orginal Article

Pharmacoeconomic evaluation of original and generic temozolomide capsules in the treatment of glioma

Ming Gu ¹
, Changdong Diao ¹^,²
, Mitchell A. Sullivan ³^,⁴
, Haixia Zhu ¹^,²
, Qi Yuan ¹^,²
, Jinmei Liu ²
, Shijun Li ¹^,²
, Yu Zhang ¹^,²
, Bin Deng ¹^,²^,^†
, Chen Shi ¹^,²^,^†

Author information +

History +

PDF (646KB)

Abstract

Aim: Original patented drugs and generic drugs using the same pharmaceutical ingredients may have different clinical efficacies and prices. This study was designed to compare the clinical efficacy and cost-effectiveness of original imported temozolomide capsules and those generic capsules manufactured domestically, with a pharmacoeconomic evaluation being performed.

Methods: In this retrospective study, 103 glioma patients from 2008 to 2018 were divided into the generic temozolomide group (72 cases) and the imported temozolomide group (31 cases). The 2-year overall survival (OS) and disease progression free survival (PFS) of the two groups were analyzed using Kaplan Meier survival curves, and the 2-year disease control rate and 2-year survival rate were calculated. The incidence of adverse reactions was also compared between the two groups. A pharmacoeconomic evaluation was performed on the two groups according to the total cost of treatment per capita.

Results: The 2-year disease control rate of the domestic drug group was 52.8% and the imported drug group was 67.7%. The 2-year survival rate of the domestic drug group was 68.10%, with the imported drug group being 74.20%. The total cost of treatment per patient/2-year PFS time in the domestic drug group was 7000.55 yuan/month; while the imported drug group was 7705.41 yuan/month. The total cost of treatment per patient/2-year OS time in domestic drug group was 5821.20 yuan/month, while the imported drug group was 7035.53 yuan/month.

Conclusion: There was no significant difference between the domestic drug group and the imported drug group in treatment efficacy and the total cost/2-year PFS time of the two groups were not significantly different. However, the total cost/2-year OS time of the domestic group was significant lower than the imported group, revealing a certain cost-effective advantage.

Keywords

Pharmacoeconomic evaluation / Clinical efficacy / Safety / Temozolomide capsules / Glioma

Cite this article

Download citation ▾

Ming Gu, Changdong Diao, Mitchell A. Sullivan, Haixia Zhu, Qi Yuan, Jinmei Liu, Shijun Li, Yu Zhang, Bin Deng, Chen Shi. Pharmacoeconomic evaluation of original and generic temozolomide capsules in the treatment of glioma. Intelligent Pharmacy, 2023, 1(1): 26-31 DOI:10.1016/j.ipha.2023.04.006

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Davis FG, McCarthy BJ. Current epidemiological trends and surveillance issues in brain tumors. Epub 2014/01/10 Expert Rev Anticancer Ther. 2001; 1 (3): 395- 401. PMID: 12113106.

[2]	Chen R, Smith-Cohn M, Cohen AL, et al. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017; 14 (5): 284- 297. Epub 2017/03/09 PMID: 28281173.

[3]	Stevens MF, Hickman JA, Stone R, et al. Antitumor imidazotetrazines. 1.Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem. 1984; 27 (2): 196- 201. PMID: 669416.

[4]	Stevens MF, Newlands ES. From triazines and triazenes to temozolomide. Eur J Cancer. 1993; 29A (7): 1045- 1047. PMID: 8499135.

[5]	Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352 (10): 987- 996. Epub 2005/03/10 PMID:15758009.

[6]	Verschuur AC, Grill J, Lelouch-Tubiana A, et al. Temozolomide in paediatric high-grade glioma: a key for combination therapy? Br J Cancer. 2004; 91 (3): 425- 429. Epub 2004/07/20 PMID:152 66331.

[7]	Shen L, Du G, Li J, et al. Interpretation on the policy of consistency evaluation of generic drugs Herald Med. 2020; 39 (5): 722- 727. Chinese. Epub 2020/08/04

[8]	Messali A, Hay JW, Villacorta R. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol. 2013; 15 (11): 1532- 1542. Epub 2013/08/09 PMID: 23935155.

[9]	Campillo-Artero C, Ortún V. Cost-effectiveness analysis: why and how. Rev Esp Cardiol. 2016; 69 (4): 370- 373. Epub 2016/03/04 PMID: 26952845.

[10]	Ding J, Li M, Li L, et al. The curative effect and safe analysis of temozolomide for neuroglioma patients. J Modern Oncol. 2019; 27 (23): 4187- 4190. Chinese. Epub 2020/07/24.

[11]	Feng L, Wu Z, He P, et al. Pharmacoeconomic evaluation of adjuvant chemotherapy regimens after 3 esophageal cancer surgries. China Pharm. 2015; 26 (14): 1887- 1889. Chinese

RIGHTS & PERMISSIONS

2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).